CD70 expression in initially diagnosed diffuse large B cell lymphoma and its clinical significance
-
摘要: 目的 分析CD70在弥漫大B细胞淋巴瘤（DLBCL）中的表达情况，并探讨其与临床预后的相关性。方法 选取2017年1月-2021年12月蚌埠医学院第一附属医院收治的初诊DLBCL患者116例，收集临床资料进行回顾性分析。检测肿瘤组织中CD70的表达情况，分析CD70表达在DLBCL患者中的临床意义。结果 116例DLBCL患者中CD70阳性表达率为80.17%，其表达与中期评估疗效、有无B症状、骨髓是否受累、Ann Arbor分期相关（P<0.05），而与性别、年龄、乳酸脱氢酶（LDH）、β2-微球蛋白（β2-MG）、B细胞淋巴瘤因子-2（BCL-2）、BCL-6、Ki-67、Hans分型、原发部位、国际预后指数（IPI）评分无显著相关性（P>0.05）。生存分析显示，CD70阳性组与CD70阴性组无进展生存期（PFS）和总生存期（OS）比较，差异有统计学意义（P<0.05），CD70阳性组患者预后更差。单因素分析显示，中期评估疗效、LDH、β2-MG、Ki-67、Hans分型、Ann Arbor分期、IPI评分及CD70表达影响患者预后。多因素分析显示，中期评估疗效、Ki-67、Hans分型、CD70是患者PFS的独立预后因素，中期评估疗效、β2-MG、Ki-67、Hans分型和CD70是患者OS的独立预后因素。结论 CD70在DLBCL中呈高表达，且与不良预后密切相关。Abstract: Objective To analyze the expression of CD70 in diffuse large B cell lymphoma (DLBCL) and its correlation with clinical prognosis.Methods A total of 116 patients newly diagnosed with DLBCL who were admitted to the First Affiliated Hospital of Bengbu Medical College from January 2017 to December 2021 were selected and their clinical data were retrospectively analyzed. The expression of CD70 in tumor tissues was detected, and the clinical significance of CD70 expression in DLBCL patients was analyzed.Results The positive expression rate of CD70 in 116 DLBCL patients was 80.17%, and its expression was related to mid-term efficacy, B symptoms, bone marrow involvement and Ann Arbor stage (P<0.05). However, CD70 expression was not associated with sex, age, lactate dehydrogenase (LDH), β2-microglobulin (β2-MG), B-cell lymphoma-2(BCL-2), BCL-6, Ki-67, Hans classification, primary site and international prognostic index (IPI) score (P>0.05). Survival analysis showed that the progression free survival (PFS) and overall survival (OS) of the CD70 positive group were significantly higher than those in the CD70 negative group (P<0.05), and the prognosis of CD70 positive patients was worse. According to univariate analysis, the prognosis of DLBCL patients was affected by efficacy, LDH, β2-MG, Ki-67, Hans classification, Ann Arbor stage, IPI score and CD70 expression. Multivariate analysis showed that mid-term efficacy, Ki-67, Hans classification and CD70 were the independent prognostic factors for PFS, and mid-term efficacy, β2-MG、Ki-67、Hans subtype and CD70 were the independent prognostic factors for OS.Conclusions CD70 is highly expressed in DLBCL and strongly associated with poor prognosis.
-
Keywords:
- CD70 /
- diffuse large B-cell lymphoma /
- prognosis /
- progression free survival /
- overall survival
-
-
[1] Schmitz R,Wright GW,Huang DW,et al.Genetics and pathogenesis of diffuse large B-cell lymphoma[J].N Engl J Med,2018,378(15):1396-1407.
[2] Guo L,Lin P,Xiong H,et al.Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment[J].Biochim Biophys Acta Rev Cancer,2018,1869(2):85-96.
[3] Fehniger TA.CD70 turns on NK cells to attack lymphoma[J].Blood,2017,130(3):238-239.
[4] Al Sayed MF,Ruckstuhl CA,Hilmenyuk T,et al.CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies[J].Blood,2017,130(3):297-309.
[5] Chapuy B,Stewart C,Dunford AJ,et al.Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes[J].Nat Med,2018,24(5):679-690.
[6] Cazzola M.Introduction to a review series:the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues[J].Blood,2016,127(20):2361-2364.
[7] Cheson SD,Fisher RI,Barrington SF,et al.Recommendations for initial evaluation,staging,and response assessment of Hodgkin and non-Hodgkin lymphoma:the Lugano classification[J].J Clin Oncol,2014,32(27):3059-3068.
[8] Blum KA,Keller FG,Castellino S,et al.Incidence and outcomes of lymphoid malignancies in adolescent and young adult patients in the United States[J].Br J Haematol,2018,183(3):385-399.
[9] Sermer D,Batlevi C,Palomba ML,et al.Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies[J].Blood Adv,2020,4(19):4669-4678.
[10] Yang M,Tang X,Zhang Z,et al.Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors[J].Theranostics,2020,10(17):7622-7634.
[11] Nakamura K,Sho M,Akahori T,et al.Clinical relevance of CD70 expression in resected pancreatic cancer:Prognostic value and therapeutic potential[J].Pancreatology,2021,21(3):573-580.
[12] Bertrand P,Maingonnat C,Penther D,et al.The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma[J].Genes Chromosomes Cancer,2013,52(8):764-774.
[13] Mondello P,Fama A,Larson MC,et al.Lack of intrafollicular memory CD4+T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma[J/OL].Blood Cancer J,2021,11(7):130.
[14] Balsas P,Veloza L,Clot G,et al.SOX11,CD70,and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma[J].Blood,2021,138(22):2202-2215.
[15] Wang QJ,Yu Z,Hanada KI,et al.Preclinical evaluation of chimeric antigen receptors targeting CD70-expressing cancers[J].Clin Cancer Res,2017,23(9):2267-2276.
[16] Shah NN,Ahn KW,Litovich C,et al.Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?[J].Blood,2021,137(10):1416-1423.
[17] Park JH,Rivière I,Gonen M,et al.Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia[J].N Engl J Med,2018,378(5):449-459.
[18] Maude SL,Laetsch TW,Buechner J,et al.Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia[J].N Engl J Med,2018,378(5):439-448.
[19] Neelapu SS,Tummala S,Kebriaei P,et al.Chimeric antigen receptor T-cell therapy-assessment and management of toxicities[J].Nat Rev Clin Oncol,2018,15(1):47-62.
[20] Zhang Y,Wang Y,Liu Y,et al.Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma:A single-arm,phase 1-2 trial[J].Leukemia,2022,36(1):189-196.
[21] Huang C,Wu L,Liu R,et al.Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma:A single-center study[J/OL].Ann Transl Med,2020,8(17):1048.
[22] Tu S,Zhou X,Guo Z,et al.CD19 and CD70 dual-target chimeric antigen receptor T-cell therapy for the treatment of relapsed and refractory primary central nervous system diffuse large B-cell lymphoma[J/OL].Front Oncol,2019,9:1350.
计量
- 文章访问数: 34
- HTML全文浏览量: 0
- PDF下载量: 2
下载:
.png)
